Tewksbury D A, Tryon E S, Burrill R E, Dart R A
Clin Chim Acta. 1986 Jul 15;158(1):7-12. doi: 10.1016/0009-8981(86)90110-5.
Although it was previously recognized that human amniotic fluid contained appreciable quantities of angiotensinogen, it remained unknown what fraction of the total is high molecular weight angiotensinogen. Fractionation of human amniotic fluid showed that high molecular weight angiotensinogen represents the major component of total angiotensinogen; 58% for 11 normotensive pregnant women and 67% for 12 hypertensive pregnant women. In contrast to plasma where high molecular weight angiotensinogen is elevated in hypertensive pregnant women as compared to normotensive pregnant women, no such difference exists for amniotic high molecular weight angiotensinogen. Serum and amniotic fluid high molecular weight angiotensinogen were compared in six subjects, and no significant correlation was found. In fetal cord blood, high molecular weight angiotensinogen represented only 5.8% of the total angiotensinogen. The site of synthesis of high molecular weight angiotensinogen remains unknown but these data suggest that it is produced in the placenta or in the maternal uterine tissue. Therefore, we propose that human high molecular weight angiotensinogen should be classified as a pregnancy-associated protein.
尽管此前已认识到人类羊水含有相当数量的血管紧张素原,但总血管紧张素原中高分子量血管紧张素原所占比例仍不清楚。对人类羊水进行分级分离显示,高分子量血管紧张素原是总血管紧张素原的主要成分;11名血压正常的孕妇中占58%,12名高血压孕妇中占67%。与血浆不同,高血压孕妇血浆中的高分子量血管紧张素原比血压正常的孕妇升高,而羊水高分子量血管紧张素原不存在这种差异。对6名受试者的血清和羊水高分子量血管紧张素原进行了比较,未发现显著相关性。在胎儿脐带血中,高分子量血管紧张素原仅占总血管紧张素原的5.8%。高分子量血管紧张素原的合成部位尚不清楚,但这些数据表明它是在胎盘或母体子宫组织中产生的。因此,我们建议将人类高分子量血管紧张素原归类为妊娠相关蛋白。